Mechano Growth Factor (MGF)
Also known as: MGF, IGF-1Ec, IGF-1Eb (rodent), Mechano Growth Factor E peptide, MGF E peptide, MGF-24aa-E peptide, Full-length MGF, Goldspink-MGF, MGF R23H (variant)
IGF-1 splice variant / peptide growth factor (IGF superfamily)
What it is
MGF is a peptide people use to support muscle repair and growth after exercise or injury, based on its role as a natural healing signal in muscle tissue. It's also studied for bone and cartilage repair. Not FDA-approved; prohibited by WADA; evidence comes largely from animal and cell studies.
The scientific side
Mechano Growth Factor (MGF) is an isoform of insulin-like growth factor 1 (IGF-1) produced by differential/alternative splicing of the IGF-1 gene. A 49-base-pair insert in exon 5 (humans; 52 bp in rodents) introduces a reading frame shift, resulting in a unique C-terminal E-domain peptide with properties distinct from systemic IGF-IEa. MGF is expressed in response to mechanical stimulation, exercise, and tissue damage in skeletal muscle and other tissues. The E-domain peptide acts as a separate growth factor: it activates mononucleated satellite (stem) cells, promotes cell proliferation, and inhibits terminal differentiation of myoblasts. Full-length MGF directly activates the IGF-I receptor (IGF-IR), though with a higher EC50 than recombinant IGF-I; at high equimolar concentrations its maximal IGF-IR stimulating effect is similar to IGF-I. MGF also activates insulin receptor isoforms IR-A and IR-B. The MGF E peptide exerts anti-apoptotic effects, including via mitochondrial, MEK-ERK1/2, and PI3K-Akt pathways, and acts as a stem cell homing factor. MGF expression declines with aging and is deficient in muscular dystrophies where the mechanotransduction mechanism (possibly involving the dystrophin complex) is impaired.
Class: IGF-1 splice variant / peptide growth factor (IGF superfamily)
Administration & storage
- Administration
- Injection into rabbit bone defect model (exact route not specified in abstract) (PMID: 32339623)Scaffold implantation (subcutaneous and intra-articular) in rabbit models (PMID: 25818452)In vitro delivery via PEGDMA microrod devices (PMID: 24908137)In vitro addition to cell culture medium (PMID: 22592456PMID: 26991004)
- Storage
- No storage conditions for MGF peptide or protein are described in the reviewed literature.
- Cautions
- No human pharmacokinetic, safety, or tolerability data for MGF peptide or full-length MGF are reported in the reviewed literature. Human use lacks clinical evidence.,MGF R23H variant has been identified in confiscated vials from illicit channels; purity, sterility, and actual content of such products cannot be verified (PMID: 28035768, PMID: 25466910).,MGF (and full-length MGF) is classified as a prohibited substance by WADA since 2005; use in athletes constitutes a doping violation.,In vitro data show MGF peptide inhibits macrophage phagocytosis and ROS generation; potential immunosuppressive effects at certain concentrations are not well characterized in humans.,Sterile technique is essential for any injectable preparation; compounded or illicitly sourced peptides carry contamination and dosing accuracy risks.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Prohibited. The substance (or class of substances) has been considered prohibited according to the regulations of the World Anti-Doping Agency (WADA) since 2005.
Not stated in reviewed literature — requires manual verification
What it's studied for
- Skeletal muscle maintenance, repair, and hypertrophy Mixed
- MGF is produced as a pulse following mechanical challenge and replenishes satellite cell pools. MGF delivery (cDNA or peptide) produces marked increases in strength of normal and diseased muscle; deficient in muscular dystrophies and aged muscle. PMID 16463438 Goldspink (2006). Impairment of IGF-I gene splicing and MGF expression associated with muscle wasting. Int J Biochem Cell Biol.
- The ability to produce MGF declines with age commensurate with declining GH. GH treatment upregulates IGF-1 gene expression, and combined with resistance exercise, more is spliced towards MGF. MGF discussed as potential means to ameliorate sarcopenia. PMID 15501012 Goldspink & Harridge (2004). Growth factors and muscle ageing. Exp Gerontol.
- MGF-24aa-E peptide significantly increased proliferative lifespan and delayed senescence of satellite cells from neonatal and young adult (but not old adult) muscle in primary human cell cultures. Hypertrophy associated with decreased reserve cells observed in all cultures. PMID 21354439 Kandalla et al. (2011). MGF-E peptide activates human muscle progenitor cells and induces an increase in their fusion potential at different ages. Mech Ageing Dev.
- MGF is only detectable after mechanical stimulation, has different expression kinetics to IGF-IEa, and initiates local muscle repair; overexpression results in hypertrophy in normal muscle. PMID 14609023 Goldspink (2003). Gene expression in muscle in response to exercise. J Muscle Res Cell Motil.
- Recombinant MGF expressed in E. coli increased proliferation of normal human myoblasts in vitro. MGF increases cellular proliferation and inhibits terminal differentiation of myoblasts. PMID 18068377 Kuznetsova et al. (2008). Producing human MGF in Escherichia coli. Protein Expr Purif.
- Bone defect healing and osteogenesis Animal studies only
- T-MGF-19E peptide promoted MC3T3-E1 osteoblast proliferation, differentiation, and mineralization in vitro. Low-dose T-MGF-19E peptide significantly promoted bone injury healing in a rabbit bone defect model. PMID 32339623 Wei et al. (2020). MGF-19E peptide promoted proliferation, differentiation and mineralization of MC3T3-E1 cell and promoted bone defect healing. Gene.
- Cartilage repair and regeneration Animal studies only
- MGF acted synergistically with TGF-β3 in silk fibroin scaffolds to increase MSC recruitment (up to 1.8–2x vs TGF-β3 alone), enhance Collagen II/aggrecan secretion, and reduce Collagen I. STM scaffolds showed best cartilage integration in rabbit osteochondral defect model. PMID 25818452 Luo et al. (2015). MGF and TGF-β3 functionalized silk scaffolds enhance articular hyaline cartilage regeneration in rabbit model. Biomaterials.
- Review: MGF is highly expressed in chondrocytes, especially in damaged cartilage (OA/trauma). MGF influences chondrocyte proliferation, migration, differentiation, inflammation, and apoptosis; its role in cartilage homeostasis remains controversial. PMID 37171185 Liu et al. (2023). The role of mechano growth factor in chondrocytes and cartilage defects: a concise review. Acta Biochim Biophys Sin.
- Anterior cruciate ligament (ACL) repair Mixed
- MGF E peptide protected ACL fibroblasts against hypoxia-induced apoptosis via caspase, MEK-ERK1/2, and PI3K-Akt pathways in vitro, and decreased apoptosis/HIF-1α while facilitating proliferation in rabbit ACL rupture model. MGF also accelerated angiogenesis via SDF-1α/CXCR4 and VEGF-α. PMID 30317597 Sha et al. (2019). MGF E peptide improves ACL repair by inhibiting hypoxia-induced apoptosis and accelerating angiogenesis. J Cell Physiol.
- MGF E peptide pretreatment improved type III collagen synthesis, decreased MMP-2 activity, and accelerated proliferation of injured human ACL fibroblasts via MEK-ERK1/2 signaling pathway in vitro. PMID 28553731 Sha et al. (2017). MGF E peptide pretreatment improves collagen synthesis and cell proliferation of injured human ACL fibroblasts via MEK-ERK1/2. Growth Factors.
- Cardiac regeneration / myocyte protection Animal studies only
- PEGDMA microrod devices loaded with MGF peptide delivered MGF for 2 weeks in vitro. MGF microrod treatment increased hMSC migration (1.72-fold, p<0.05) and protected neonatal rat ventricular myocytes from hypoxia-induced apoptosis (increased Bcl-2 expression, p<0.05). PMID 24908137 Doroudian et al. (2014). Sustained delivery of MGF peptide from microrods attracts stem cells and reduces apoptosis of myocytes. Biomed Microdevices.
- Periodontal ligament regeneration Mixed
- MGF produced under occlusion force enhanced PDL remodeling in vivo. Mechanochemical coupling effect mediated by Fyn-FAK kinases and MAPK pathway enhanced PDLSC differentiation toward fibroblasts in vitro. Enhanced PDL regeneration under combined MGF and occlusal force verified in vivo. PMID 38193124 Zhao et al. (2024). Mechanochemical coupling of MGF mediates periodontal regeneration. Bioeng Transl Med.
- Neuroprotection / neural stem cell effects under hypoxia Animal studies only
- In vitro: exogenous MGF administration increased NSC proliferation and migration in all oxygen conditions (anoxic, hypoxic, normoxic). MGF application upregulated HIF-1α gene expression in anoxic conditions. Suggests neuroprotective/proliferative role of MGF in ischemia. PMID 39403354 Aydıntuğ-Gürbüz et al. (2024). The Effects of IGF1 and MGF on Neural Stem Cells in Hypoxic Conditions. Basic Clin Neurosci.
- Immune modulation (macrophage function and overtraining) Animal studies only
- Overload training (11 weeks) in rats increased MGF mRNA in peritoneal macrophages 92-fold vs controls. In vitro, MGF peptide (1, 10, 50, 100 ng/mL) inhibited ROS generation; MGF peptide impaired macrophage phagocytosis in a dose-independent manner. PMID 22592456 Xiao et al. (2013). Overload training inhibits phagocytosis and ROS generation of peritoneal macrophages: role of IGF-1 and MGF. Eur J Appl Physiol.
- Muscle adaptation after orthognathic surgery Human observational
- Prospective study in 29 adult patients: MGF mRNA was significantly upregulated (P<0.005) in masseter muscle 6 months after orthognathic surgery, with concurrent MyHC isoform shift, indicating adequate muscle adaptation. PMID 18567511 Maricic et al. (2008). MGF- and myostatin-mRNA regulation in masseter muscle after orthognathic surgery. Oral Surg Oral Med Oral Pathol.
- Doping / sports performance enhancement (misuse context) In vitro only
- A 'full-length MGF' derivative (12264.9 Da, IGF-1Ec-related, with C-terminal lysine elimination and R109H substitution) was identified in illicit channels and implemented into doping control assays. Detectable at 0.25 ng/mL using immunoaffinity purification + nanoscale LC-HRMS. WADA-prohibited since 2005. PMID 25466910 Thevis et al. (2014). Mass spectrometric characterization of a biotechnologically produced full-length MGF relevant for doping controls. Growth Horm IGF Res.
- MGF R23H, a variant of mechano growth factor, was identified in confiscated vials. In vitro plasma metabolism experiments demonstrate MGF R23H has good stability and should be detectable in urine. PMID 28035768 Cox et al. (2017). Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Test Anal.
- Full-length MGF directly activates IGF-IR with EC50 7.83 nmol/L (vs 0.86 nmol/L for IGF-I). At high equimolar concentrations, maximal IGF-IR stimulation by full-length MGF similar to IGF-I. Human MGF and Goldspink-MGF (24aa E peptide versions) showed no IGF-IR activation in these assays. PMID 26991004 Janssen et al. (2016). Potency of full-length MGF to induce maximal activation of the IGF-I R is similar to recombinant human IGF-I at high equimolar concentrations. PLoS One.
Safety signals
- MGF peptide inhibited macrophage phagocytosis (dose-independent) and ROS generation (at 1, 10, 50, 100 ng/mL) in vitro in rat peritoneal macrophages, suggesting potential immunosuppressive effects. PMID 22592456
- Full-length MGF obtained from illicit channels contained a modified sequence (C-terminal lysine elimination, R109H substitution) compared to native IGF-1Ec; identity and purity of illicitly sourced products cannot be assured. PMID 25466910
- MGF R23H confiscated variant: in vitro plasma stability was good, suggesting prolonged systemic exposure if administered; clinical safety implications unknown. PMID 28035768
- No oncogenic side effects from MGF-E peptide alone were observed in muscle cell cultures (noted as an advantage over IGF-1); however, formal safety/toxicology studies in humans are not reported in the reviewed literature. PMID 21354439
Contraindications
- No formal contraindications are stated in the reviewed literature for MGF as a therapeutic agent. WADA-prohibited status constitutes a regulatory contraindication for competitive athletes. PMID 25466910
Protocol
200 mcg intramuscular, 2-3x per week, post-workout. Cycle: 4-6 weeks.
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| In vitro (added to cell culture medium) | 1, 10, 50, 100 ng/mL (MGF peptide) | Not specified (in vitro incubation) | in_vitro | Research PMID 22592456 |
| In vitro (microrod device in cell culture) | MGF peptide encapsulated in PEGDMA microrods; elution measured by HPLC over 2 weeks | 2 weeks sustained delivery | in_vitro | Research PMID 24908137 |
| Scaffold implantation (subcutaneous and intra-articular) | MGF embedded in silk fibroin scaffolds (exact concentration not specified in abstract) | 7 days (subcutaneous); 2 months (subcutaneous); duration of osteochondral implant experiment not specified | animal | Research PMID 25818452 |
| Injection (rabbit bone defect model; exact route not specified in abstract) | Low-dose T-MGF-19E peptide (exact dose not specified in abstract) | Not specified | animal | Research PMID 32339623 |
| Not specified in abstract (rabbit ACL rupture model) | MGF E peptide (exact concentration not specified in abstract for in vivo rabbit model) | Not specified | animal | Research PMID 30317597 |
| Not specified | Detectable at 0.25 ng/mL (analytical detection threshold, not a therapeutic dose) | Not applicable (doping control context) | human | Research PMID 25466910 |
| In vitro (KIRA bioassay, HEK293 cells) | EC50 7.83 nmol/L (95% CI 4.87–12.58) for IGF-IR activation by full-length MGF; EC50 73.11 nmol/L (42.87–124.69) for IR-A; EC50 35.10 nmol/L (17.52–70.33) for IR-B | Not applicable (in vitro receptor activation assay) | in_vitro | Research PMID 26991004 |
| intramuscular | 200 mcg | post-workout, 2-3x per week · 4-6 weeks | bodybuilders and strength athletes seeking muscle hypertrophy | [Community] |
| intramuscular | 100 mcg | post-workout, 2-3x per week · 4-6 weeks | intermediate biohackers or first-time MGF users starting conservatively | [Community] |
| subcutaneous | 200 mcg | post-workout, 2-3x per week · 4-6 weeks | biohackers preferring subcutaneous administration for convenience | [Community] |
| intramuscular | 200 mcg | post-workout, on training days only · 4 weeks | bodybuilders stacking MGF with IGF-1 LR3 for synergistic anabolic effect | [Community] |
| intramuscular | 300 mcg | post-workout, 3x per week · 4-6 weeks | advanced bodybuilders and experienced peptide users seeking higher-end dosing | [Community] |
| intramuscular | 200 mcg | post-workout, injected into multiple muscle bellies per session · 4-6 weeks | bodybuilders targeting multiple lagging muscle groups simultaneously | [Community] |
| intramuscular | 200 mcg | 3x per week on non-consecutive training days · 6 weeks on, 4 weeks off | natural or enhanced athletes cycling MGF for long-term use | [Community] |
| intramuscular | 200 mcg | post-workout, 2-3x per week · 4-6 weeks | athletes using MGF for soft-tissue injury recovery and muscle repair | [Community] |
All studies (18)
- PMID 18567511 Human observational
Muscle adaptation after orthognathic surgery - PMID 14609023 Mixed
Skeletal muscle maintenance, repair, and hypertrophy - PMID 15501012 Mixed
Skeletal muscle maintenance, repair, and hypertrophy - PMID 16463438 Mixed
Skeletal muscle maintenance, repair, and hypertrophy - PMID 18068377 Mixed
Skeletal muscle maintenance, repair, and hypertrophy - PMID 21354439 Mixed
Skeletal muscle maintenance, repair, and hypertrophy - PMID 28553731 Mixed
Anterior cruciate ligament (ACL) repair - PMID 30317597 Mixed
Anterior cruciate ligament (ACL) repair - PMID 38193124 Mixed
Periodontal ligament regeneration - PMID 22592456 Animal studies only
Immune modulation (macrophage function and overtraining) - PMID 24908137 Animal studies only
Cardiac regeneration / myocyte protection - PMID 25466910 In vitro only
Doping / sports performance enhancement (misuse context) - PMID 25818452 Animal studies only
Cartilage repair and regeneration - PMID 26991004 In vitro only
Doping / sports performance enhancement (misuse context) - PMID 28035768 In vitro only
Doping / sports performance enhancement (misuse context) - PMID 32339623 Animal studies only
Bone defect healing and osteogenesis - PMID 37171185 Animal studies only
Cartilage repair and regeneration - PMID 39403354 Animal studies only
Neuroprotection / neural stem cell effects under hypoxia
Frequently asked
What is MGF and how does it differ from IGF-1?
MGF (Mechano Growth Factor) is a splice variant of the IGF-1 gene (also called IGF-1Ec in humans, IGF-1Eb in rodents). A 49-base-pair insert in exon 5 causes a reading frame shift, producing a unique C-terminal E-domain peptide that is distinct from systemic IGF-IEa. While both come from the IGF-1 gene, MGF is expressed locally in response to mechanical stimulation and tissue damage, whereas systemic IGF-1 (liver type) is the main circulating form. MGF's E-domain peptide activates satellite (stem) cells and has anti-apoptotic effects, whereas systemic IGF-IEa primarily upregulates protein synthesis (PMID 16463438, PMID 15501012, PMID 14609023).
What does the research say about MGF for muscle growth and recovery?
Preclinical research suggests MGF plays a role in muscle repair and maintenance. It is produced following mechanical challenge or injury, replenishes the satellite (stem) cell pool, and its overexpression has resulted in hypertrophy in animal models. Delivery of MGF cDNA or peptide has been reported to produce increases in muscle strength in normal and diseased muscle in preclinical settings. In human cell culture, the MGF-24aa-E peptide increased proliferative lifespan and fusion potential of satellite cells from neonatal and young adult donors. However, no controlled human clinical trials on MGF for muscle growth are reported in the reviewed literature.
What dose of MGF should I use for muscle building?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: in vitro studies have used MGF peptide concentrations of 1–100 ng/mL in cell culture, and receptor activation studies identified EC50 values of ~7.83 nmol/L for IGF-IR stimulation by full-length MGF. No human dosing data are reported in the reviewed literature. There are no established safe or effective human doses.
Is MGF legal to use?
MGF and related substances have been classified as prohibited by the World Anti-Doping Agency (WADA) since 2005. Its regulatory status with the US FDA and Health Canada is not explicitly stated in the reviewed literature and requires verification with those agencies. Use in competitive sport is a doping violation.
Can I stack MGF with other peptides like IGF-1 or BPC-157?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: MGF E peptide has been studied for muscle satellite cell activation and tissue repair (PMID 21354439, PMID 16463438); BPC 157 has been studied in separate contexts. No studies in the reviewed literature address the combination of MGF with other peptides in humans.
Where can I buy MGF peptide?
I don't recommend vendors or sources. Please consult a licensed provider. Note that MGF is WADA-prohibited and products sold via illicit channels have been identified with modified sequences and unknown purity (PMID 25466910, PMID 28035768).
Is MGF safe to inject?
No human safety or tolerability data for injectable MGF are reported in the reviewed literature. In vitro, MGF peptide showed immunosuppressive effects on macrophage function at certain concentrations. Full-length MGF variants have been found in illicitly sourced vials with sequence modifications and unverified purity. Without clinical trial safety data, the risks of human self-injection cannot be characterized. Please consult a licensed healthcare provider.
Can MGF help with sarcopenia or age-related muscle loss?
The reviewed literature suggests that the ability to produce MGF declines with aging, commensurate with declining growth hormone levels, and this is associated with reduced muscle maintenance capacity (PMID 15501012, PMID 16463438). GH treatment combined with resistance exercise may increase IGF-1 splicing toward MGF in older individuals. In human cell culture, MGF-E peptide increased satellite cell proliferation from neonatal and young adult donors but not old adult donors. No human clinical trials on MGF for sarcopenia are reported in the reviewed literature. Consult a licensed healthcare provider for treatment options.
Will MGF show up on a drug test?
Yes. MGF is WADA-prohibited since 2005. Analytical methods using immunoaffinity purification followed by nanoscale LC-high resolution mass spectrometry can detect full-length MGF at concentrations as low as 0.25 ng/mL in adapted doping control assays. The MGF R23H variant has been shown to have good plasma stability and is expected to be detectable in urine. Detection windows in humans are not established in the reviewed literature.
Has MGF been tested in humans?
The reviewed literature does not report controlled human clinical trials evaluating MGF as a therapeutic intervention. Human cell culture studies (e.g., primary satellite cells, ACL fibroblasts) have been conducted (PMID 21354439, PMID 28553731). One human observational study documented MGF mRNA upregulation in masseter muscle biopsies after orthognathic surgery in 29 patients. Receptor activation studies used human cell lines (HEK293) in vitro. In vivo human pharmacokinetic, efficacy, and safety data are absent from the reviewed literature.